Skip to search formSkip to main contentSkip to account menu

Goserelin

Known as: 6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) 2-(aminocarbonyl)hydrazide, Goserelin [Chemical/Ingredient], Luteinizing hormone-releasing factor (pig), 6-(O-(1,1-dimethylethyl)-D-serine)-10-deglycinamide-, 2-(aminocarbonyl)hydrazide 
A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates… 
National Institutes of Health

Related topics

Related topics

15 relations

Broader (1)

Antineoplastic Agents, Hormonal
Goserelin 10.8 MG Drug Implant [Zoladex]In BloodNCIt Antineoplastic Agent Terminologyagonists

Narrower (3)

Goserelin AcetateICI-118630Zoladex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Highly Cited
2015
Highly Cited
2015
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
BACKGROUND Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH… 
Highly Cited
2015
Highly Cited
2015
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
To the Editor: In the PALOMA3 study, Turner et al. (July 16 issue)1 report that the addition of palbociclib to fulvestrant… 
Highly Cited
2005
Highly Cited
2005
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Highly Cited
2004
Highly Cited
2004
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
Highly Cited
2002
Highly Cited
2002
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
Highly Cited
2002
Highly Cited
2002
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association…
PURPOSE Current adjuvant therapies have improved survival for premenopausal patients with breast cancer but may have short-term… 
Highly Cited
2001
Highly Cited
2001
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Highly Cited
1997
Highly Cited
1997
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
BACKGROUND We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin… 
Review
1997
Review
1997
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85…
PURPOSE Although androgen suppression results in a tumor response/remission in the majority of patients with carcinoma of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)